News

News

NEWS
Jump to Publications

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Febuary 22nd, 2024

NeoChord Appoints Martin B. Leon, M.D. as Executive Chair of the U.S. Early Feasibility Study of the NeoChord Transcatheter NeXuS System

March 14th, 2022

Transfemoral Mitral Valve Repair System Wins CRT 2022 Best Innovation Competition

February 28th, 2022

NeoChord Announces Positive 30-day Results with Transcatheter NeXuS System for Mitral Chordal Repair Using Multiple Chords to a Single Anchor

November 22nd, 2021

NeoChord Announces Successful Completion of First in Human Procedure with its NeoChord NeXuS Transcatheter Mitral Chordal Repair Technology

October 4th, 2021

NeoChord Raises Additional Financing to Drive Catheter‐based Program Development, Bringing Total Series D Funding to over $32 Million

April 23rd, 2019

NeoChord Announces $25 Million Series D Financing to Accelerate Development of Two Transcatheter Chordal Repair Programs

November 5th, 2018

NeoChord Announces Successful Completion of First Beating Heart Repair Procedures in China

September 3rd, 2018

Neochord DS1000 System Successfully Treats 20th Patient in Combination with Other Beating Heart Procedures

April, 2018

NeoChord Announces a Research Collaboration with the Skirball Center for Innovation at the Cardiovascular Research Foundation

January, 2018

Andrew ElBardissi, M.D. Named to NeoChord Board of Directors

June, 2017

NeoChord Names J. Alex Martin Chairman of the Board

January 23rd, 2017

First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation;

November 9th, 2016

NeoChord passes 500 patient treatment milestone follow-up data on 127 patients out to two years presented at EACTS;

October 28th, 2016

NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation;

May 13th, 2016

NeoChord announces appointment of Alex Jonkers as VP of European Commercial Sales and milestone of over 400 patients treated with the DS1000 System;

May 5th, 2016

J. Alex Martin joins NeoChord Board of Directors;

April 4th, 2016

David H. Adams, MD and Michael A. Borger, MD PhD to Serve as National Principal Investigators for NeoChord’s U.S. Pivotal Trial.

March 29th, 2016

NeoChord Again Awarded NUB Status 1 in Germany

February 10th, 2016

NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.

Learn More

Helpful Links

PUBLICATIONS

Combining echocardiographic and anatomic variables to predict outcomes of mitral valve repair with the NeoChord procedure

January, 2021

Transapical off-pump echo-guided mitral valve repair with neochordae implantation mid-term outcomes

January, 2021

Minimally invasive procedure of retensioning of artificial chords implanted using NeoChord DS1000 under echocardiographic guidance: the first case in Poland

December 8th, 2020

Feasibility of novel transapical off pump beating heart mitral valve repair in a patient with dextrocardia and situs inversus

August 1st, 2020

Direct Beating Heart NeoChord Mitral Valve Re-Repair from Dr. Albertini/Cotignola

May 19th, 2020

NeoChord System as an Alternative Option Upon Transmitral Pressure Gradient Elevation in the MitraClip Procedure

March 9th, 2020

Is trans-apical off-pump neochord implantation a safe and effective procedure for mitral valve repair?

August 28th, 2019
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation.

NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency. The NeoChord Artificial Chordae Delivery System, Model DS1000, meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.

NEOCHORD, DS1000, RECHORD, NEOCHORD CONSULTCONNECT, CONNECTCARD, ACCHORD, ULTRACHORD, the stylized logos, and Transforming Mitral Valve Repair are registered trademarks or service marks of NeoChord, Inc.

CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.

CONTACT

(952) 698-7800

info@neochord.com

NeoChord, Inc
10900 73rd Ave North Suite 101
Maple Grove, MN 55369